Fixing the Broken Business Model of Rare Disease Gene Therapies | Craig Martin

What happens when a life-saving gene therapy is developed for a patient population of only 30 people? The traditional pharmaceutical business model completely breaks down.

In this episode of Out of the Lab, host Nico sits down with Craig Martin, CEO and Founder of the Orphan Therapeutics Accelerator, to dissect the radical operational and financial shifts required to bring advanced therapies to ultra-rare disease communities. Craig shares how his non-profit accelerator is rewriting the playbook, from rescuing and "ring-fencing" shelved pharma assets to establishing a shared clinical development network (Orphan ClinDevNet) that spreads infrastructure costs across multiple therapies.

They dive deep into the gritty operational realities of advanced therapies: the staggering financial burdens placed on caregivers, the ethical dilemmas of placebo-controlled arms in pediatric trials, and why a reimbursement system built for chronic, recurring pills fundamentally fails a one-time cure.

Discussion Points:

• The Shared Infrastructure Fix: Discover how the Orphan ClinDevNet partners with specialized CDMOs and CROs to build a repeatable framework, avoiding the need to reinvent the manufacturing wheel for every single ultra-rare indication.

• The Non-Profit Win-Win for IP: Learn how biotech companies can safely out-license or ring-fence shelved rare disease assets to a non-profit accelerator without losing the commercial upside for larger, subsequent indications.

• The $1 Trillion Problem: Why leaving rare diseases untreated costs the US healthcare system over $1 trillion annually, and why a high one-time cure price tag is actually a collective macroeconomic win.

The Logistical Nightmare of Patient Access: An inside look at the hidden friction points of advanced therapies—from navigating state-by-state Medicaid reimbursement hurdles to seeking OIG opinions for travel and lodging support for economically disadvantaged families.

Timestamps:

• 00:00 - Introduction & The Rare Disease Market Failure

• 02:14 - Scaling Efficiencies: What is the Orphan ClinDevNet?

• 05:30 - Rescuing Shelved IP via a Non-Profit Accelerator Model

• 08:45 - The Operational and Regulatory Bottlenecks (CMC Batches & Placebos)

• 12:15 - The Real Cost of Caregiving: Travel, Lodging, and OIG Regulations

• 15:40 - Why Our Reimbursement System Fails One-Time Cures

• 19:10 - Platform Approvals & The Future of "Plausible Mechanism" Access